Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: MOHSEN S ELALFY, PROF.
- Email: AMIRADIABETES@YAHOO.COM
Study Locations
-
-
-
Cairo,, Egypt
- Pediatric Hematology clinic, Ain Shams University Egypt
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- • Subjects with overload secondary to thalassemia major
Exclusion Criteria:
• with HIV positive or have active HCV.
- A history of serious immunologic hypersensitivity to any medication such as anaphylaxis or angioedema.
- Participation in a previous investigational drug study within the 30 days preceding screening.
- A woman of childbearing potential must have a negative serum pregnancy test at screening. She must use a medically acceptable form of birth control during the study and for a month afterwards who are pregnant or breast-feeding.
- An inability to adhere to the designated procedures and restrictions of this protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: vitamin c
25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
|
adjuvant vitamin c with iron chelator.
Other Names:
|
|
Other: iron chelator
Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
|
iron chelator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vit C to Augment iron chelation
Time Frame: 12 months
|
assess safety and efficacy of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.
|
12 months
|
|
vitamin c augmenting effect of iron chelator
Time Frame: 12 month
|
better reduction in serum ferritin, LIC and cardiac T28 in group receiving vitamin c
|
12 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
adverse related events
Time Frame: 12 month
|
safety and occurrence of AEs in both studied groups
|
12 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: MOHSEN S ELALFY, PROF., Ain Shams University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Thalassemia
- beta-Thalassemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Antioxidants
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Vitamins
- Ascorbic Acid
- Deferiprone
Other Study ID Numbers
Other Study ID Numbers
- vitamin c and iron chelator
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.